Selank and Semax are the two most widely discussed nootropic peptides to come out of Russian neuropharmacology, and they are routinely compared in online communities. But the comparison is often superficial — “Selank for anxiety, Semax for focus” — without examining why these peptides do what they do or when one is genuinely preferable to the other.
Here is what the evidence shows, where it stops, and how the people I coach usually choose between them.
At a Glance
| Property | Selank | Semax |
|---|---|---|
| Origin | Tuftsin analog (immunopeptide) | ACTH(4-10) analog (melanocortin) |
| Primary Action | Anxiolytic, immunomodulatory | Nootropic, neuroprotective |
| Key Pathways | GABA, serotonin, BDNF | Dopamine, BDNF, melanocortin |
| Evidence Level | Moderate (Russian clinical trials) | Moderate (Russian clinical trials, stroke data) |
| Route | Intranasal | Intranasal |
| Standard Dose | 200-400 mcg, 2-3x daily | 200-600 mcg, 2-3x daily |
| Cycle | 14-21 days | 10-30 days |
| Regulatory | Approved in Russia only; not FDA/EMA-approved | Approved in Russia only; not FDA/EMA-approved |
| Effect Onset | Minutes (anxiolytic); days (cognitive) | Minutes to hours (cognitive) |
| Dependence Risk | None documented | None documented |
| Stimulatory? | No — calming | Yes — mildly activating |
The Fundamental Difference: Two Lineages, Two Targets
To understand why these peptides behave differently, you need to understand where they came from.
Selank: Born from the Immune System
Selank is a synthetic analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by enzymatic cleavage of immunoglobulin G in the spleen. Tuftsin’s primary role is immunomodulatory — it enhances phagocytosis and natural killer cell activity. The researchers at the Institute of Molecular Genetics added a Pro-Gly-Pro tripeptide to tuftsin’s C-terminus to increase its metabolic stability and discovered that this modified peptide had potent anxiolytic and nootropic effects beyond the original immunomodulatory activity.
The anxiolytic mechanism involves multiple systems:
- GABAergic modulation. Selank enhances GABAergic transmission without directly binding GABA receptors, avoiding the sedation and dependence profile of benzodiazepines.
- Serotonin metabolism. In rodent studies, Selank alters serotonin and its metabolite 5-HIAA in brain regions such as the hippocampus and hypothalamus, with effects that differ between mouse strains (Narkevich et al., 2008; Semenova et al., 2010).
- BDNF upregulation. Selank increases brain-derived neurotrophic factor expression, which contributes to both anxiolytic and cognitive effects over time.
- Enkephalin modulation. Selank influences the expression of enkephalin genes, connecting it to the endogenous opioid system’s role in emotional regulation.
Semax: Born from the Stress Hormone System
Semax is a synthetic analog of the ACTH(4-10) fragment — a portion of adrenocorticotropic hormone that retains the neurotropic activity of ACTH without the adrenal-stimulating effects. Where Selank is derived from the immune system, Semax is derived from the stress-response system, specifically the melanocortin pathway.
The nootropic mechanism operates through:
- Dopaminergic enhancement. Semax increases dopamine and its metabolites in the striatum and nucleus accumbens, contributing to motivation, attention, and working memory.
- Melanocortin receptor activation. MC3 and MC4 receptor engagement produces neuroprotective and neuroplasticity-enhancing effects.
- BDNF upregulation. Like Selank, Semax robustly increases BDNF, but through different upstream pathways — melanocortin signaling rather than GABAergic/serotonergic modulation.
- NGF modulation. Semax also influences nerve growth factor, supporting neuronal survival and differentiation.
The critical distinction: Selank calms the brain while enhancing function. Semax stimulates the brain while enhancing function. Both increase BDNF, but through different signaling cascades, which is why their subjective effects are so different.
The Evidence: Head to Head
Neither peptide has been tested head-to-head in a single trial. We must compare their evidence bases separately.
Selank: The Anxiety Data
The strongest human evidence for Selank comes from Russian clinical trials in generalized anxiety disorder:
- A double-blind comparison with medazepam (a benzodiazepine) in GAD patients showed comparable anxiolytic efficacy on the Hamilton Anxiety Scale, with Selank producing no sedation, cognitive impairment, or dependence (Seredenin et al., 2009).
- Selank received Russian regulatory approval in 2009 for anxiety disorders and neurasthenia.
- Cognitive improvements in anxious patients were documented over 14-day courses, with effects more pronounced in the second week.
The limitation: these trials were conducted by the developer’s research ecosystem, published primarily in Russian, and have not been independently replicated internationally.
Semax: The Cognitive and Stroke Data
Semax has a broader clinical evidence base than Selank, partly because it has been approved in Russia since the 1990s for multiple indications:
- Stroke recovery. The most robust data. Semax demonstrated neuroprotective effects in ischemic stroke patients, reducing infarct volume and improving neurological outcomes when administered within the first 12 hours (Gusev et al., 1997).
- Cognitive enhancement. Clinical trials in patients with cognitive impairment showed improvements in attention, memory, and information processing speed over 10-day courses.
- Optic nerve atrophy. Semax is approved in Russia for optic nerve conditions, with data showing improvement in visual function.
- ADHD-related research. Preliminary data suggesting benefits in attention deficit presentations, though this indication is not formally approved.
Semax has somewhat stronger Western interest due to its neuroprotective stroke data, which has been cited in English-language neuroscience reviews.
What I See When Coaching Patients
In practice, the choice between Selank and Semax maps relatively clearly to the primary complaint:
Selank patients are those whose cognitive difficulties are downstream of anxiety. They cannot concentrate because they are anxious. They cannot sleep because their mind races. They describe mental fog that lifts when they are calm (on vacation, after exercise). For these patients, Selank addresses the root cause — anxiety — and the cognitive improvement follows.
Semax patients are those with primary cognitive complaints without significant anxiety. They feel mentally sluggish, have difficulty with sustained attention, or describe a “brain fog treatment approaches” that is not anxiety-driven but rather a flat, hypo-aroused state. Many people with post-COVID persistent cognitive impairment fall into this category. Semax provides the dopaminergic push that these patients need.
Combined patients represent the most frequent presentation — people with both anxiety and cognitive impairment for whom the complementary mechanisms make sense. The Selank prevents the anxiety that Semax’s mild stimulatory effect might otherwise exacerbate, while Semax provides the cognitive drive that Selank alone does not fully deliver.
Practical Comparison: Choosing Your Protocol
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
Neither peptide is approved by the FDA, EMA, or BfArM, and the FDA lists both among compounding substances that may present significant safety risks.
When to Choose Selank
- Primary complaint is anxiety with secondary cognitive impairment
- History of poor response to stimulatory compounds (caffeine sensitivity, stimulant side effects)
- Sleep disturbance is a significant component (Selank does not interfere with sleep)
- Benzodiazepine tapering has been suggested as a use, but this is untested, and any benzodiazepine taper belongs under medical supervision
- Concurrent autoimmune mechanisms or inflammatory condition where immunomodulation may be beneficial
When to Choose Semax
- Primary complaint is cognitive impairment without significant anxiety
- Post-stroke cognitive rehabilitation
- Hypo-aroused, low-motivation presentation (“brain fog” without anxiety)
- ADHD-type attention difficulties
- Optic nerve or visual processing concerns
When to Combine
- Mixed anxiety-cognitive presentation (the most common scenario)
- Post-COVID neurological sequelae with both anxiety and cognitive components
- People who tried Semax alone and found it slightly overstimulating
- People who tried Selank alone and found it calming but insufficient for cognitive demands
Combined Protocol
| Parameter | Selank | Semax |
|---|---|---|
| Morning dose | 200 mcg per nostril | 200-300 mcg per nostril |
| Midday dose | 200 mcg per nostril | 200-300 mcg per nostril |
| Evening dose | 200 mcg per nostril (optional) | Not recommended (stimulatory) |
| Cycle | 14-21 days | 10-21 days |
When stacking, I recommend starting each peptide separately for at least one short course to understand individual response before combining. Some people find that Selank alone is sufficient, and adding Semax provides marginal benefit. Others find the combination significantly superior to either alone. Individual neurochemistry matters. No trial has tested Selank and Semax together, so this combined schedule reflects practice rather than trial data, and stacking unapproved peptides multiplies the unknowns (see Peptide Stacking).
Mechanism Comparison: Why They Are Complementary
The theoretical case for viewing Selank and Semax as complementary is that their mechanisms converge on neuroplasticity (BDNF) while diverging on neurotransmitter modulation:
Convergence: Both increase BDNF expression. This shared effect supports neuroplasticity, synaptic strengthening, and long-term cognitive resilience. The combined BDNF signal from two different upstream pathways may be more robust than either alone, though this has not been tested directly.
Divergence: Selank modulates GABA and serotonin (calming). Semax modulates dopamine and melanocortin (activating). These systems are complementary rather than redundant. A brain that is both calm and engaged — GABAergic stability with dopaminergic drive — is precisely the neurochemical state associated with optimal performance.
This is not a theoretical construct. The pharmacological profile of peak performance states consistently involves adequate GABAergic tone (preventing anxiety-driven interference) with sufficient dopaminergic activity (providing motivation and attention). Selank and Semax approximate this balance through two different molecular mechanisms.
Safety Comparison
| Concern | Selank | Semax |
|---|---|---|
| Dependence | None documented | None documented |
| Tolerance | Not observed in 14-21 day courses | Not observed in standard courses |
| Sedation | No | No |
| Overstimulation | No | Possible in sensitive individuals |
| Insomnia risk | No | Low (avoid evening dosing) |
| Nasal irritation | Mild, occasional | Mild, occasional |
| Immunomodulation | Yes (tuftsin-derived) | Minimal |
| Cardiovascular | No known effects | No known effects |
| Autoimmune caution | Yes (immune activation) | No specific concern |
Both peptides have excellent safety profiles across published data. The primary practical difference is that Semax can be mildly overstimulating in anxiety-prone individuals, while Selank has essentially no activation concern. Neither produces dependence, which is a meaningful differentiator from conventional anxiolytics and stimulants.
The Bottom Line
Selank and Semax are complementary, not competing. Selank is the better choice when anxiety is the primary driver of cognitive difficulty. Semax is the better choice when cognitive impairment exists without significant anxiety. The combination is rational when both presentations coexist, which they frequently do, although it has never been tested in a trial. The evidence for both is moderate — grounded in Russian clinical trials and preclinical data — and neither has undergone the rigorous international replication that would elevate confidence further. In the published studies, these are among the best-tolerated peptides for neurological optimization, with the important caveat that individual response varies, the evidence base is geographically concentrated, and neither is approved outside Russia and a few neighbouring countries.
Back to Selank Overview | All Peptide Articles
References
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. “Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia.” Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096.
- Narkevich VB, Kudrin VS, Klodt PM, et al. “Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study.” Eksp Klin Farmakol. 2008;71(5):8-12. PMID: 19093364.
- Gusev EI, Skvortsova VI, Chukanova EI. “Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency.” Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(2):35-40.
- Eremin KO, Kudrin VS, Saransaari P, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochem Res. 2005;30(12):1493-1500. DOI: 10.1007/s11064-005-8826-8.
- Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaia MM. “Experimental optimization of learning and memory processes by selank.” Eksp Klin Farmakol. 2010;73(8):2-5. PMID: 20919548.
Disclaimer: This article is provided for educational purposes and reflects one physician’s clinical approach. Selank and Semax are approved in Russia but not by the FDA or EMA. It is not a substitute for individualized medical care. Consult a qualified physician before beginning any peptide protocol.
